-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Moderna today announced the results of the first interim analysis of the Phase III COVE study, which showed that its new coronavirus COVID-19 vaccine mRNA-1273 has an effective rate of 94.5%.
the analysis confirmed 95 cases of neo-coronavirus infection, including 90 in the placebo group and only 5 in the mRNA-1273 group.
: uk.reuters.com Moderna plans to seek FDA emergency approval in the coming weeks, based on a final analysis of 151 patients, with an average follow-up time of more than two months.
COVE study is currently evaluating the efficacy of the 100 mcg dose of COVID-19 vaccine mRNA-1273 in 30,000 participants aged 18 and older in the United States at significant risk of COVID-19 infection.
subjects were given the drug twice, 28 days apart.
the main endpoint of the trial is the prevention of symptomatic COVID-19 diseases, the main secondary objectives include the prevention of severe COVID-19 diseases and the prevention of SARS-CoV-2 infection.
Moderna noted that 11 cases of severe COVID-19 were found in the first interim analysis, all of which occurred in the placebo group.
of the new crown vaccine for the new rna (Photo: NIH website)